FIELD: medicine.
SUBSTANCE: invention relates to compounds active against nuclear receptors, namely to compounds that modulate activity RORα and/or RORγ.
EFFECT: compounds that can be used for the treatment and/or prevention of inflammatory, metabolic and autoimmune diseases or disorders.
18 cl, 2 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2719422C2 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2734261C2 |
| SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
| DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
| ACTIVE COMPOUNDS WITH RESPECT TO BROMO-DOMAINS | 2015 |
|
RU2743074C2 |
| HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
| USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
| IMIDAZOPYRIDINE COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2782743C2 |
| MULTIKINASE INHIBITOR COMPOUND AND ITS CRYSTALLINE FORM AND USE | 2017 |
|
RU2723985C1 |
| USE OF FORMYL PEPTIDE RECEPTOR 2 AGONISTS FOR TREATING INFLAMMATORY EYE DISEASES | 2014 |
|
RU2768730C2 |
Authors
Dates
2024-03-19—Published
2015-07-31—Filed